Adam Vogel PhD is Chief Science Officer and founder of Redenlab, a US-Australian medtech company. Redenlab provide digital speech testing solutions to guide decision-making in clinical trials and health research. 

Adam is also Associate Professor and Director of the Centre for Neuroscience of Speech at The University of Melbourne where his team work towards improving speech, language and swallowing function in people with progressive and acquired neurological conditions. He has held continuous NHMRC fellowships since 2009 and is currently funded by an NHMRC Dementia Fellowship. Adam is a past recipient of Humboldt Fellowship based at the Hertie Institute for Clinical Brain Research, Tübingen Germany.

Adam holds a PhD in behavioural neuroscience from The University of Melbourne and degrees in psychology and speech science from the University of Queensland. He is an honorary speech therapist at Great Ormond Street Hospital London, where he undertook his early clinical training. Adam is a consultant speech pathologists in the Friedreich Ataxia Clinic and Cognitive Disorders Clinic (Eastern Health) in Melbourne. His group have strategic clinical research alliances with the Eastern Cognitive Disorders Clinic, the Calvary Health Service Bethlehem, the Neuropsychiatry Unit, Royal Melbourne Hospital, the University Hospital Tübingen, Germany, Usher Institute of Population Health Sciences and Informatics at The University of Edinburgh, City University, London, Department of Neurology at the University of California San Francisco as well as The University of Texas at Austin. Adam's work has been recognized through awards from the Bethlehem Griffiths Research Foundation, the Australian Speech Science & Technology Association and the Australian Institute of Policy and Science.